Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...
Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded ...
ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis ...
Preparations underway to advance AP-101 into confirmatory Phase 3 clinical trial with initiation aimed for late 2026 ZURICH, March 19, 2026--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage ...
AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
The cameras are still rolling for now, but behind the scenes, one of television’s most recognizable entertainment brands is heading toward its final act. “NBCUniversal is making changes to our ...
“Homeless and at-risk New Yorkers need a lifeline in the immediate term, and the governor must join the Assembly and the Senate in expanding the HAVP pilot to $250 million.” Gov. Kathy Hochul ...
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of ...
CHARLOTTE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Fontaine Modification, North America’s leading provider of post-production truck services, now offers fleets unrivaled visibility throughout the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results